Company intelligence / Profile preview
Guangzhou Baiyunshan Pharmaceutical Holdings
- Ownership
- Private
- Employees
- ~20000
- Development stage
- Other
Overview
Guangzhou Baiyunshan Pharmaceutical Holdings has a large commercial portfolio with over 1,200 pharmaceutical products, including both traditional Chinese medicine and modern pharmaceuticals. The pipeline includes innovative drugs in oncology and cardiovascular disease areas. Notable recent launches include generic sildenafil citrate ("JinGe") and memantine hydrochloride. The group holds more than 300 products in the National Medical Insurance Catalogue, indicating broad clinical adoption.
- Therapeutic areas
- NeurologyInfectious DiseasesMen's HealthEndocrinologyOtherCardiovascular
- Modalities
- Small moleculeBiologicTraditional Chinese MedicineAntibioticPeptides
- Industry
- Biotech
Drug pipeline
7 assets6 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Guangzhou Baiyunshan Pharmaceutical Holdings.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangzhou Baiyunshan Pharmaceutical Holdings.